IL2 and melanoma: Initially Food and Drug Administration−approved for treatment of metastatic renal cell carcinoma and melanoma in the 1990s (Rosenberg, 2014), before the resurgence of Treg biology, high doses of IL-2 are used as stimulatory immunotherapy.